On November 11, 2022 AimedBio reported that its candidate of ‘P018’ has been selected as a "novel therapeutics-based expansion research" project by the Korean Drug Development Project (KDDF) and will receive research funds to derive its lead over the next two years.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

P018 is an antibody targeting the tumor microenvironment (TME) which activates immune cells such as T cells and NK cells by removing tumor-associated macrophages (TAM).

AimedBio expects to solve unmet medical needs in solid cancers such as brain tumors and lung cancer through combination of P018 and immuno-oncology drugs.

(Press release, AimedBio, NOV 11, 2022, View Source;s_keyword=&s_where=&start=0 [SID1234656922])